Literature DB >> 7460252

Oral prostaglandin E2 in ductus-dependent pulmonary circulation.

E D Silove, J Y Coe, M F Shiu, J D Brunt, A J Page, S P Singh, M D Mitchell.   

Abstract

Prostaglandin E2 (PGE2) was administered orally, in doses of 12-65 microgram/kg at intervals of 1-4 hours, to 12 neonates in whom the pulmonary circulation depended on patency of the ductus arteriosus. After an oral dose, both oxygen saturation (SaO2) and plasma PGE2 concentration increased consistently within 15-30 minutes, reaching values comparable to those during i.v. infusions. Treatment continued for 5 days to 4 months. In eight infants, PGE2 withdrawal resulted in a decrease of SaO2, from a mean of 75 +/- 7% to 57 +/- 10% (+/- SD). The ductus remained responsive for long periods--in four infants, for over 3 months. Consequently, surgery could be delayed until the infants and their pulmonary arteries had grown. Side effects during oral therapy were similar to those during i.v. infusion but were less severe in this series. The effectiveness and simplicity of oral PGE2 administration have advantages over i.v. administration, especially for long-term treatment.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7460252     DOI: 10.1161/01.cir.63.3.682

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  PROSTAGLANDINS IN CONGENITAL HEART DISEASE.

Authors:  M Sharma; M Sasikumar; S D Karloopia; B N Shahi
Journal:  Med J Armed Forces India       Date:  2011-07-21

2.  Pharmacological manipulation of the ductus arteriosus.

Authors:  E D Silove
Journal:  Arch Dis Child       Date:  1986-09       Impact factor: 3.791

3.  Operative balloon dilatation for pulmonary atresia with intact ventricular septum.

Authors:  J R Hamilton; S F Fonseka; N Wilson; D F Dickinson; D R Walker
Journal:  Br Heart J       Date:  1987-10

4.  Myocardial infarction in a neonate with cyanotic congenital heart disease.

Authors:  M M de Moor; S M Vosloo; D G Human
Journal:  Pediatr Cardiol       Date:  1986       Impact factor: 1.655

Review 5.  Pharmacologic manipulation of the ductus arteriosus in the neonate: a physiologic basis and current state of the art.

Authors:  S K Sanyal; A Abu-Melha
Journal:  Indian J Pediatr       Date:  1988 Jan-Feb       Impact factor: 1.967

Review 6.  The future potential of eicosanoids and their inhibitors in paediatric practice.

Authors:  T Shimizu
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

7.  Pulmonary artery growth during treatment with oral prostaglandin E2 in ductus dependent cyanotic congenital heart disease.

Authors:  P MacMahon; P F Gorham; R Arnold; J L Wilkinson; D I Hamilton
Journal:  Arch Dis Child       Date:  1983-03       Impact factor: 3.791

8.  Prostaglandin E2 administration in infants with ductus-dependent cyanotic congenital heart disease.

Authors:  B D Thanopoulos; A Andreou; C Frimas
Journal:  Eur J Pediatr       Date:  1987-05       Impact factor: 3.183

9.  Outcome of treatment for neonates referred to a supraregional cardiac centre 1976-78.

Authors:  D F Dickinson; R Arnold; J L Wilkinson
Journal:  Arch Dis Child       Date:  1982-05       Impact factor: 3.791

10.  Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease.

Authors:  E D Silove; D G Roberts; J V de Giovanni
Journal:  Arch Dis Child       Date:  1985-11       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.